Abstract Body

BCA2 (breast cancer-associated gene 2) is an E3 ubiquitin ligase that serves as a co-factor in the restriction imposed by Tetherin on HIV-1. We recently demonstrated that BCA2 also has Tetherin-independent activity. Particularly, BCA2 targets HIV-1 Gag for lysosomal degradation, impairing virus assembly. Since many antiviral factors modulate the NF-κB pathway, we sought to explore if BCA2 is harnessing this innate cascade to further limit HIV-1

To study the role of BCA2 on NF-κB, gene expression and NF-κB-inducible luciferases assays were performed. Results obtained from these studies were corroborated by depleting cells from BCA2 and its co-factors using shRNAs. To examine the implication of the BCA2-mediated regulation of NF-κB in HIV-1 infectivity, replication and transcriptional assays were conducted in CD4+ cells. To identify the molecular mechanism by which BCA2 modulates this pathway, the post-translational modifications of NF-κB components were analyzed as well as their subcellular distribution

Here we show that BCA2 is induced by NF-κB-activating cytokines and its up-regulation provides a negative feedback on NF-κB. Knockdown assays revealed that UBC9 is a critical BCA2 co-factor to inhibit the NF-κB pathway. UBC9 mediates the SUMOylation of IκBα, which in turn impairs the nuclear translocation of NF-κB. To explore if BCA2 participates in this process, we assessed IκBα’s post-translational modifications. Remarkably, the levels of SUMOylated IκBα increase in cells overexpressing BCA2 (2-fold) whereas its phosphorylation levels diminish (10-fold). Conversely, depletion of UBC9 or BCA2 leads to a significant reduction of SUMOylated IκBα and a corresponding increase in its phosphorylation levels. In vitro SUMOylation studies revealed that BCA2 enhances IκBα SUMOylation, demonstrating for the first time that BCA2 serves as a SUMO-ligase in the regulation of the NF-κB pathway. Consistent with this, BCA2 blocks the nuclear translocation of NF-κB. Since HIV-1 needs NF-κB to enhance its replication, we studied the biological implication of the BCA2-dependent inhibition of this pathway in HIV-1 infectivity. BCA2 reduces HIV-1 transcription up to 4-fold in CD4+ cells. However, HIV-1 partially circumvents this hurdle by decreasing the steady-state levels of BCA2 via a yet unidentified mechanism

BCA2 poses several barriers to HIV-1 infection: not only does BCA2 prevent assembly and release of nascent virions, but also restricts HIV-1 at the transcriptional level